Literature DB >> 31636342

Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group.

Dennis A Eichenauer1,2, Annette Plütschow1,2, Michael Fuchs1,2, Sylvia Hartmann3, Martin-Leo Hansmann3, Boris Böll1,2, Bastian von Tresckow1,2, Peter Borchmann1,2, Andreas Engert4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31636342     DOI： 10.1038/s41375-019-0609-3

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  1 in total

1.  Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach.

Authors:  Phoebe T M Cheng; Diego Villa; R Petter Tonseth; David W Scott; Alina S Gerrie; Ciara L Freeman; Tom Pickles; Andrea C Lo; Pedro Farinha; Jeffrey W Craig; Graham W Slack; Randy D Gascoyne; François Bénard; Don Wilson; Brian Skinnider; Joseph M Connors; Laurie H Sehn; Kerry J Savage
Journal:  Blood Adv       Date:  2021-09-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.